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Abstract
Objective—Progressive supranuclear palsy (PSP) has been conceptualized as a large-scale
network disruption, but the specific network targeted has not been fully characterized. We sought
to delineate the affected network in patients with clinical PSP.
Methods—Using task-free fMRI, we mapped intrinsic connectivity to the dorsal midbrain
tegmentum (dMT), a region which shows focal atrophy in PSP. Two healthy control groups (1
young, 1 older) were used to define and replicate the normal connectivity pattern, and patients
with PSP were compared to an independent matched healthy control group on measures of
network connectivity.
Results—Healthy young and older subjects showed a convergent pattern of connectivity to the
dMT, including brainstem, cerebellar, diencephalic, basal ganglia, and cortical regions involved in
skeletal, oculomotor, and executive control. Patients with PSP showed significant connectivity
disruptions within this network, particularly within cortico-subcortical and cortico-brainstem
interactions. Patients with more severe functional impairment showed lower mean dMT network
connectivity scores.
Interpretation—This study defines a PSP-related intrinsic connectivity network in the healthy
brain and demonstrates the sensitivity of network-based imaging methods to PSP-related
physiological and clinical changes.
INTRODUCTION
Progressive supranuclear palsy syndrome (PSP-S) presents with progressive gait instability,
axial rigidity, ophthalmoparesis, and cognitive-behavioral impairment.1 Cognitive deficits
often occur early and may include executive dysfunction, apraxia of speech, nonfluent
aphasia, mental slowing, and cognitive inflexibility.1–5 Behavioral symptoms, such as
apathy, compulsions, obsessions, and utilization/imitation behavior, emerge at varied points
along the course.6 Typical PSP-S (also referred to as Richardson syndrome) features early,
prominent gait and oculomotor symptoms that strongly predict underlying PSP pathology, a
four-repeat tauopathy featuring characteristic neuronal and glial tau inclusions in basal
ganglia, diencephalon, brainstem, cerebellum, and specific cortical regions.7–9 In other
patients with PSP pathology, cognitive or behavioral deficits arise first and may remain the
most conspicuous feature.9 Consistent with this clinical heterogeneity, PSP pathology is
now classified as a subtype of frontotemporal lobar degeneration with tau-immunoreactive
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inclusions (FTLD-tau).10 For clarity, throughout this manuscript we use PSP-S to refer to
the typical PSP syndrome and PSP to refer to the histopathological entity.
PSP-S has long been proposed as a network-based disorder.11–13 This concept rests on the
observation that PSP-targeted regions feature robust axonal interconnections in non-human
primates. The advent of “resting-state” or, perhaps preferably, “task-free” functional MRI
(fMRI) has enabled researchers to identify large-scale intrinsic connectivity networks
(ICNs) in humans by mapping regions with temporally correlated low frequency blood
oxygen level-dependent signal fluctuations.14 ICN mapping has been used to link healthy
human network architectures to the cortically-predominant atrophy patterns seen in
Alzheimer’s disease and frontotemporal dementia.15, 16 Early degeneration in typical PSP-S,
however, targets subcortical and brainstem structures17, 18 that have been less well
characterized with ICN methods.19 Because patients with PSP-S often lack severe cortical
atrophy,17, 18 cortical dysfunction in PSP-S has been proposed to reflect disconnection of
cortical structures from their subcortical inputs and projection targets.20, 21
We hypothesized that ICN analysis would identify a PSP-related network in healthy subjects
and that patients with PSP-S would show connectivity breakdowns within this ICN, even
when volumetric changes are incorporated into the analysis. We further sought to explore
relationships between connectivity disruption and clinical impairment. Our findings identify
a dorsal midbrain-anchored, PSP-related anatomical system in humans and illustrate the
sensitivity of ICN methods to network dysfunction and clinical severity in patients with
PSP-S.
SUBJECTS AND METHODS
Subjects
Controls—Functional and structural MRI scans from 25 young healthy controls (HC1)
were acquired from the New York University (NYU) test-retest dataset (10 males/15
females; ages 22–49; http://www.nitrc.org/frs/?group_id=274) generously made available by
Milham and colleagues. As described in the primary publication,22 these subjects had no
history of psychiatric or neurological illness. For our ICN analyses, we used the first scans
provided for each NYU subject. To validate our HC1 ICN findings and extend the analysis
to healthy older controls, a second healthy control group (HC2) was selected from the UCSF
Memory and Aging Center database. HC2 consisted of 26 right-handed subjects (13
females) between 60 and 70 years of age. Finally, a third healthy control group (HC3; N =
36, 24 females, see Table) was selected for comparison to the PSP-S group. HC3 was
composed of two healthy control subjects matched to each patient with PSP-S for age,
gender, handedness, and education. HC2 and HC3 subjects did not overlap; they were
recruited from the San Francisco community through advertisements and underwent a
neurological examination and neuropsychiatric assessments as described previously.23 All
were required to have a Clinical Dementia Rating (CDR) scale total score of 0, a Mini-
Mental State Examination (MMSE) score of 27 or higher, no significant history of
neurological disease or structural lesion on MRI, and a consensus diagnosis of cognitively
normal. Diagnoses were rendered within 180 days of MRI scanning in all but two subjects,
who were diagnosed as cognitively normal within a year prior to and after scanning.
Quantitative eye movement evaluation was performed in 24 of the HC3 subjects within 90
days of scanning using methods described previously.24
Patients—The PSP-S group consisted of 18 patients with a diagnosis of “probable PSP”
based on published consensus clinical diagnostic criteria.25 This group included all patients
in the UCSF database who (1) received a research diagnosis of probable PSP within 180
days of MRI, (2) had undergone task-free fMRI, (3) had no significant history of other
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neurological disease or structural pathology on MRI (aside from changes consistent with
PSP-S), and (4) had measured head movement < 3 mm translation and 3 degrees rotation.
Twenty patients met criteria 1–3; two were excluded due to excessive movement. Sixteen of
18 patients with PSP-S were taking central nervous system acting medications at the time of
the neuroimaging and clinical evaluations, including 9 patients who were taking
dopaminergic medications (see Supplementary Methods for details). Patients underwent a
thorough clinical evaluation including a history, general neurological examination, MMSE,
and Clinical Dementia Rating Scale (CDR) by a staff behavioral neurologist within 90 days
of scanning. Most patients were further evaluated with a bedside neuropsychological screen
(n=12), the PSP rating scale26 (PSPRS, n=14), the Unified Parkinson’s Disease Rating Scale
(UPDRS, n=14), and quantitative eye movement evaluation24 (n=13) all within 90 days of
scanning. A subset of the patients with PSP-S was recruited as part of a pilot clinical
treatment trial; all patients, however, underwent MRI before study drug administration. Four
of eighteen patients studied had died by the time of this writing, and all four underwent
autopsy. Of these, all 4 had a primary neuropathological diagnosis of PSP.
All subjects or their surrogates provided informed consent prior to participation, and all
study procedures were approved by the local institutional review boards.
Image acquisition
NYU dataset—MR imaging of NYU young healthy controls (HC1) was obtained on a
Siemens Allegra 3.0 Tesla scanner. A T1-weighted magnetization prepared gradient echo
(MP-RAGE) sequence was also obtained [time to repetition (TR) 2500 ms, time to echo
(TE) 4.35 ms, time to inversion (TI) 900ms, flip angle 8 degrees, 176 slices, field of view
256 mm]. Task-free fMRI scans were obtained over 6.5 minutes, during which subjects were
instructed to relax with eyes open, using a T2*-weighted sequence [TR 2000 ms, TE 25 ms,
flip angle 90 degrees, 39 slices, matrix size 64 × 64, field of view 192 mm, acquisition voxel
size 3 × 3 × 3 mm, 197 volumes].
UCSF dataset—MR imaging of older controls (HC2 and HC3) and patients with PSP
occurred at the UCSF Neuroscience Imaging Center (NIC) on a Siemens Trio 3.0 Tesla
scanner. For coregistration purposes, a volumetric magnetization prepared rapid gradient
echo (MPRAGE) MRI sequence was used to obtain a T1-weighted image of the entire brain
in sagittal slices during the same session (TR: 2300 ms; TE: 2.98 ms; inversion time, 900
ms; FA, 9°). These images were reconstructed as a 160 × 240 × 256 matrix with 1 mm3
spatial resolution. Task-free fMRI images were obtained using an eight minute T2*-
weighted sequence, during which subjects were instructed to remain awake with their eyes
closed. Thirty-six interleaved axial slices (3 mm thick including a gap of 0.6 mm) were
imaged parallel to the plane connecting the anterior and posterior commissures using a T2*-
weighted echo planar imaging sequence [TR: 2000 ms; TE: 27 ms; flip angle: 80°; field of
view: 230 × 230 mm2; matrix size: 92 × 92; in-plane voxel size: 2.5 × 2.5 mm] with an
online gradient adjustment for head motion compensation.
Image preprocessing and analysis
Structural Imaging—Using the SPM8 VBM8 toolbox, the PSP-S and HC3 T1-weighted
images were processed using the VBM8 default estimation settings, segmented into grey and
white matter, spatially normalized with the SPM8 default low-dimensional spatial
normalization, subjected to a light cleanup (to remove any remaining non-brain tissue from
the data), modulated, corrected for non-linear warping only, and smoothed with a 12 mm
full width at half maximum isotropic Gaussian kernel. Correction for total intracranial
volume was not performed as non-linear modulation and normalization corrects for
variations in brain size. The resulting grey and white matter maps were subsequently used to
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assess the atrophy pattern in our PSP-S group, model the effects of brain structure on
intrinsic connectivity in PSP-S, and compare the utility of ICN and VBM approaches for
detecting PSP-S-related changes.
Functional imaging: head motion assessment—Subject head motion was assessed
by using the rigid body parameters provided by the realign algorithm in SPM5. Parameters
for a given volume in the timeseries were compared to the parameters for the previous
volume, creating a set of values that captured the amplitude of volume-to-volume changes.
Using these values, mean root-mean-square (RMS) values were calculated for translation
and mean Euler angles for rotation, as these summary metrics have been shown to correlate
with network connectivity strength.27 The PSP-S and HC3 groups showed no significant
differences in translational or rotational movement (see Table).
Functional imaging: preprocessing and ROI-based intrinsic connectivity
analysis—Using SPM5, UCSF subjects’ functional images were spatially realigned, slice
time corrected, coregistered to each subject’s structural T1-weighted image, normalized to
the Montreal Neurological Institute (MNI) T1 template, and smoothed with a 4 mm
Gaussian kernel. Handling of NYU images was identical except that the functional images
were normalized directly to the SPM5 EPI template.
Consistent with our previous approaches,15 we selected a seed for the ROI-based ICN
analysis from regions shown to be significantly atrophied in a previous VBM study
performed at our center on an independent (non-overlapping) group of patients with PSP-
S.17 Among the six grey matter regions previously identified, we selected the dorsal
midbrain tegmentum (dMT) because, in contrast to the other regions, the dMT was seated
further from the subarachnoid space (mitigating concerns regarding mixed tissue
compartment signals) and fell within a region imaged in all subjects (unlike the pontine
tegmentum region, which fell partly outside the inferior edge of the task-free fMRI
bounding box for some subjects). Further supporting this seed choice, recent clinico-
anatomical studies have shown that dMT volume correlates with vertical saccade velocity, a
function classically impaired in typical PSP-S.28 The dMT ROI consisted of a 4 mm radius
sphere centered at the local maximum from the previous VBM study comparing PSP-S to
controls (5, −15, −8).17 Using SPM8, we calculated the average BOLD signal intensity of all
voxels within this ROI at each TR over each subject’s eight-minute scan. We used the
resulting time series as a covariate of interest in a whole-brain statistical parametric
regression analysis to derive images corresponding to the dMT intrinsic functional
correlation map for each subject. A total of six 4 mm radius spherical ROIs embedded in the
CSF (left posterior and right anterior lateral ventricles) and white matter (left and right
frontal and left and right parietal corona radiata) were included as covariates to reduce
effects of physiological noise. We omitted the global signal and motion parameters as
nuisance covariates based on recent work showing that inclusion of these measures exerts a
negative effect (global signal regression) or no effect (motion parameters) on ICN test-retest
reliability29 and may unnecessarily reduce fMRI signal (motion parameters).30 One sample
t-tests were performed separately in HC1 and HC2 to identify clusters with significant
intrinsic connectivity to the dMT in healthy young and older subjects at a cluster-forming
height threshold of p < 0. 0001 uncorrected and a cluster extent threshold of p < 0.001
corrected for family-wise error. To identify smaller brainstem and subcortical regions with
highly significant correlation to the dMT, we also visualized the HC1, HC2, and HC1/HC2
overlap maps at a voxel-level, family-wise error-corrected threshold of p < 0.05 (no extent
threshold). We employed this rigorous discovery (HC1) and replication (HC2) strategy
because few previous ROI-based ICN studies have focused on brainstem ROIs and to ensure
that the novel ICN delineated here showed topographical consistency across the adult age
spectrum, consistent with other more extensively studied ICNs.31, 32
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To compare the strength of the dMT-associated ICN in PSP-S to healthy matched controls
(HC3), we entered the PSP-S and HC3 subject-level ICN maps into a second-level, random
effects analysis masked to voxels for which non-zero fMRI signal was present in all subjects
(to avoid including brainstem regions covered in some but not all subjects). Two-sample t-
tests were performed to evaluate linear contrasts representing PSP-S < HC3 and PSP-S >
HC3. Next, we used the BPM toolbox33 to enter each subject’s VBM grey and white matter
maps as voxel-wise covariates to control for the effects of atrophy on ICN strength. Results
of atrophy-uncorrected and corrected two-sample t-tests were thresholded using joint
probability distribution thresholding34 with joint height and extent thresholds of p < 0.01
and p < 0.05 (for visualization purposes), corrected across the search volume, in keeping
with our previous work.35 For these analyses, we applied an explicit dMT-seeded ICN mask,
derived from the HC2 group one-sample t-test (voxel height threshold of p < 0.005
uncorrected, extent threshold of p < 0.01), chosen to generously constrain the search volume
to regions within the dMT-associated ICN.
Functional imaging: ICN node pair matrix-based analysis and graph
theoretical metrics—Because the seed ROI-based method only provides information
about each voxel’s connectivity to the chosen seed ROI, we used the HC2-derived dMT-
seeded ICN, to create a group of “intrinsic connectivity clusters” for an ROI matrix-based
analysis, allowing us to examine all pairwise ROI interactions. Cluster ROI creation
followed methods described in the Supplementary Materials. The mean voxel-wise BOLD
signal timeseries for each resulting ROI was used to create partial correlation matrices, with
all other ROIs, that represent the ROI pair-wise correlation coefficients after controlling for
white matter and CSF nuisance regressors. These group-level pair-wise correlations were
visualized as matrices to facilitate assessment of connectivity reduction patterns in PSP-S.
Two-sample t-tests identified ROI pair-wise differences in intrinsic connectivity between the
PSP and HC3 groups, thresholded using false discovery rate correction for multiple
comparisons at p < 0.05.
To augment the matrix-based ICN analyses described above, we used the methods of graph
theory36 to further characterize the normal network architecture and to derive metrics for
group-level contrasts. In graph theoretical terms, each ROI represents a node, and the
connectivity between each pair of ROIs represents an edge. We used the ICN matrices from
the HC2 group to generate a graph in Cytoscape (http://www.cytoscape.org) based on an
edge-weighted, force-directed layout algorithm that configures the nodes in space according
to the weights of their edges, in this case based on the node pair correlation coefficients
transformed to z-scores and thresholded at z > 0.31 (r = 0.3). To gauge the sensitivity of
network architecture to matrix thresholding, we generated two further graphs, one with a
more lenient and another with a more stringent threshold (Supplementary Figure 3).
To further explore differences between PSP and HC3 with regard to network architecture,
we calculated total flow, mean clustering coefficient, and mean path length from the
adjacency matrices for each subject, thresholded using the same three thresholds used to
generate the HC2 graphs. Total flow is a measure of weighted degree, computed as the sum
of a node’s weighted pairwise connections. Clustering coefficient is a node-wise metric that
captures the degree to which a node’s 1st level neighbors are connected to one another. Path
length describes to the shortest connectional distance required to travel between two given
nodes in the graph. Two-sample t-tests were used to compare nodal total flow and clustering
coefficient values between PSP-S and HC3, thresholded using false discovery rate
correction for multiple comparisons at p < 0.05. Mean total flow, clustering coefficient, and
path length were compared between groups using Mann-Whitney U tests performed for each
HC2 graph threshold. Equations used to calculate graph metrics were implemented in
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Matlab using the Brain Connectivity Toolbox and MatlabBGL (http://www.cs.purdue.edu/
homes/dgleich/packages/matlab_bgl/).37
Correlation between dMT-associated ICN connectivity and clinical severity—
To assess the relationship between PSP-S clinical severity and intrinsic connectivity, we
derived a dMT-asociated ICN score for each patient with PSP-S. This score was computed
as the mean beta value across all voxels of each subject’s dMT-associated ICN map within
an HC2-derived dMT network mask (thresholded at a joint height and extent threshold of p
< 0.001). Because the resulting ICN scores were non-normally distributed within the PSP-S
group, we used Spearman correlation to examine the relationship between mean dMT ICN
score and CDR sum of boxes, UPDRS, and PSPRS. These clinical measures were chosen
because they summarize clinical severity in PSP and showed ample dynamic range without
floor or ceiling effects. In addition, we examined Spearman correlations between mean dMT
ICN score and vertical saccade velocity, measured in degrees per second. Age, gender, and
movement parameters showed no significant correlation with the dMT-associated ICN
score, and these potential confounders were therefore omitted from the analyses to improve
power.
Comparisons between ICN and VBM findings in PSP-S—In an exploratory
analysis, we compared the sensitivity of task-free fMRI and VBM analyses for detecting
network degeneration in PSP-S. At each voxel, effect size for the PSP < HC3 contrast was
calculated using voxel-wise group means and pooled standard deviations derived from the
subject-level ICN or VBM grey matter maps. Maps were created to visualize where ICN
analysis generated a greater effect size than VBM and vice versa (see Supplementary
Methods).
Statistical thresholding principles for image analyses—A consistent thresholding
strategy was used for the primary imaging analyses. One-sample t-tests for network
definition were thresholded at a cluster-forming height threshold of p < 0.0001 and a cluster
extent threshold of p < 0.001 corrected for family-wise error across the whole brain. Major
study hypotheses (2 sample t-tests comparing PSP-S to HC3) were tested at a joint height
and extent threshold of p < 0.01 as well as p < 0.05 (for visualization purposes), cluster-level
corrected across the search volume.34 Thresholds not used for hypothesis testing were
guided by their specific purpose. For example, network masks were thresholded to
generously constrain group-level analyses to a specific ICN without expanding the search
volume to the entire brain.
RESULTS
The healthy brain features an ICN composed of PSP-vulnerable brain regions
Our first goal was to identify a healthy brain network composed of regions known to
degenerate in PSP-S. To pursue this objective, we conducted ICN analyses in two
independent healthy control groups (young (HC1) and older (HC2) controls). Using ROI-
based task-free fMRI analysis, we identified regions that showed significant intrinsic
connectivity with the dMT, a primary focus of grey matter atrophy in PSP-S17 that
correlates with vertical saccade velocity in patients with PSP-S and other neurodegenerative
disorders.28 As expected, the ICNs converged in the healthy young and older control
“network discovery and replication” groups (HC1 and HC2; Figure 1). Despite seeding this
ICN analysis with a focal midbrain ROI, we detected a distributed network pattern that
included additional brainstem, cerebellar, diencephalic, basal ganglia, and cortical regions
known to degenerate along differing gradients in typical and atypical PSP-S.9 and to
cooperate in the healthy brain to support skeletal and ocular motor function, gait, action
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planning, and cognitive-behavioral control. Because prominent behavioral and speech praxis
deficits can accompany typical PSP-S, we noted with interest that the dMT-associated ICN
also included the pregenual anterior cingulate and frontoinsular cortices, which show early
degeneration in the behavioral variant of frontotemporal dementia (bvFTD),38 as well as the
frontal operculum/dorsal anterior insula, a focus of atrophy in patients with nonfluent
aphasia and apraxia of speech.39 Importantly, the dMT-associated ICN was consistent across
different adult age groups, scanners, and acquisition protocols, confirming that it represents
a robust and reproducible ICN.
PSP-S is associated with reduced connectivity throughout the dorsal midbrain
tegmentum-associated ICN
Next, we sought network connectivity changes in patients with PSP-S. Compared to 36
matched healthy controls (HC3), patients with PSP-S showed distributed network
connectivity reductions throughout the dMT-seeded ICN (Figure 2, Supplementary Table 1),
most prominent in striatum, thalamus, cerebellum, and cortical regions. Omitting the dMT-
associated network mask revealed minimal changes; a few clusters of reduced connectivity
in PSP-S extended just beyond the mask boundaries or into contiguous regions, such as the
superior and middle temporal gyri. Importantly, no regions of increased connectivity were
identified in PSP-S vs. controls (with or without masking) even at the lower statistical
threshold included in Figure 2 for visualization purposes. After atrophy correction, the PSP-
S < HC3 contrast differed little, with only the dorsal midbrain and SMA showing less
extensive dMT connectivity reduction in PSP-S (Supplementary Figure 2). No regions of
increased connectivity in PSP-S were identified in the atrophy-corrected model.
PSP-S is associated with distributed node pair connectivity reductions throughout the
dorsal midbrain tegmentum-associated ICN matrix
To map a more comprehensive network architecture among the regions identified with the
seed ROI-based approach, we created data-driven ROIs representing the major nodes of the
dMT-associated ICN (Figure 3, Supplementary Figure 1, Supplementary Table 2, clusters
available upon request from the corresponding author). PSP-S showed pair-wise
connectivity reductions distributed throughout this matrix (Figure 3E), especially in cortico-
subcortical and cortico-brainstem connections. No node pair connection showed increased
connectivity. This analysis extended the seed-based ICN findings by showing that regions
distributed throughout this neural system show reduced connectivity with each other, not
only with the dMT.
The healthy configuration of the fully specified network is graphed in Figure 4 using an
edge-weighted, force-directed algorithm to capture nodes’ relationships with each other.
This approach illustrated the centrality of the mesothalamic junction (MTJ, just rostral to the
dMT), basal ganglia (a cluster spanning anterior caudate, putamen, and pallidum), and
thalamus. These “hub-like” nodes feature high degree centrality and provide a functional
link between the cortex and brainstem/cerebellum. Comparing each node’s total flow (the
sum of its weighted edges) in PSP-S and HC3, we identified the MTJ and several key
cortical regions as showing significant total flow reductions in PSP-S (Figure 4). All
network nodes showed reduced clustering coefficients in PSP-S (FDR-corrected, p < 0.05).
Mean total flow and clustering coefficient (computed across all nodes) showed significant
reductions in PSP-S (Supplementary Table 3). No significant differences were found for
mean path length at any of the three HC2 graph thresholds.
PSP-S connectivity reductions correlate with clinical impairment
To explore whether ICN measures prove sensitive to disease severity, we assessed
correlations between the mean dMT-associated ICN score (see Methods) and clinical
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measures that summarize functional integrity. Initially, no significant correlations were
found. Examination of these data, however, revealed one conspicuous outlier: a patient with
PSP-S having severe clinical impairment despite a relatively high mean dMT-associated
ICN score. Excluding this outlier recovered a significant inverse relationship between mean
dMT-associated ICN strength and the CDR sum of boxes score (ρ = −0.662, p = 0.004;
Figure 5), indicating that patients with more advanced disease showed weaker network
connectivity. Similar but non-significant negative correlations were seen for the PSPRS (ρ =
−0.345, p = 0.249) and UPDRS (ρ = −0.319, p = 0.288) with the outlier excluded. We
further observed a trend toward slower downward saccades in patients with lower ICN
scores (ρ = 0.511, p = 0.074; outlier included). Importantly, patients with PSP-S who were
or were not taking dopaminergic agents showed no difference in mean dMT connectivity (t
= 0.409, p = 0.688), a finding which held after exclusion of the outlier in the connectivity-
behavior correlation analyses, who was taking carbidopa/levodopa (t = 0.942, p = 0.361).
Intrinsic connectivity and morphometric analyses play complementary roles in detecting
network degeneration in PSP-S
Early detection and disease-monitoring PSP-S biomarkers may need to detect physiological
changes that precede gross atrophy. We hypothesized that ICN analysis would prove more
sensitive to early disease in regions with little or no atrophy while structural imaging
(VBM), which involves less methodological noise, would outperform ICN methods in
regions already showing significant atrophy. To test these ideas, we used the PSP-S < HC3
contrasts to compare the voxel-wise effect sizes of dMT connectivity reduction to those
derived from VBM. As predicted, we found that dMT connectivity showed larger effect
sizes in network regions functionally connected to areas where significant atrophy had
already emerged. On the other hand, VBM generally produced larger effect sizes for regions
already showing significant atrophy (Figure 6). These findings suggest that ICN and VBM
approaches may provide complementary information and raise the speculation that ICN
mapping may prove most valuable during early-stage disease.
DISCUSSION
This study establishes an ICN, anchored by the dorsal midbrain, whose nodes include the
brainstem, basal ganglia, diencephalic, cerebellar, and cortical regions that show atrophy and
tau aggregation in PSP.1, 9, 17 Hence, PSP-S, like other neurodegenerative disease
syndromes,15 reflects injury to a specific large-scale cortical-subcortical system that can be
mapped in the healthy brain with task-free fMRI. We further demonstrated that this method
detects robust, distributed, and functionally relevant connectivity reductions in PSP-S within
a network of skeletal and ocular motor control structures as well as in regions that
participate in executive, social-emotional and speech-language functions. These findings
suggest that the heterogeneous clinical presentations of PSP pathology may reflect the
gradient of pathology within nodes of the broader network outlined here. Patients whose
disease begins in the dorsal midbrain and its closest motor control system affiliates will
present with typical PSP-S but would be predicted to later develop behavioral and language
deficits when pathology reaches the relevant cortical network nodes. In contrast, patients
whose pathology begins in cortical nodes may present with bvFTD, progressive nonfluent
aphasia, or a corticobasal syndrome, depending on the node and hemisphere affected first,
before disease spreads along network lines to produce the defining oculomotor and gait
impairments that lead clinicians to predict PSP as the underlying histopathology. Perhaps
most importantly, we found that intrinsic connectivity disruption correlated with overall
clinical severity and detected PSP-S-related network dysfunction in regions lacking
significant grey matter atrophy.
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Relationship of present findings to PSP anatomical literature
Recently, Whitwell et al40 performed a task-free fMRI analysis in patients with PSP-S. First,
they performed a seed-based analysis using an ROI containing the entire bilateral thalami.
Although several regions showed increased or decreased connectivity to this thalamic seed,
it is difficult to place these results in an anatomical context given the diverse anatomical and
intrinsic functional connections of the thalamus.41 Second, these authors applied
independent component analysis in healthy controls to identify a “basal ganglia network”,
which showed connectivity reductions in PSP-S compared to the same healthy controls. This
strategy, using the same control subjects to select and analyze the network, reduces
confidence in the reported group differences due to the problem of statistical dependency.42
Here, we used a data-driven seed-based approach to define a reproducible dMT-associated
network targeted in PSP-S compared to an independent sample of healthy controls. We
observed no increases in network connectivity, perhaps reflecting the anatomical specificity
of our approach.
The present work builds on a foundation of previous PSP-S neuropathological and imaging
studies. Although the core pathological distribution of PSP has been recognized since the
disorder’s initial description,1 more recent structural imaging and pathological analyses have
shed light on the cortical vulnerability patterns associated with typical and atypical
PSP.9, 17, 18 Recent work using diffusion tensor imaging has underlined the role of white
matter tract degeneration, especially within the superior cerebellar peduncle.43, 44 Positron
emission tomography studies analyzing the covariance of metabolic patterns across patients
and controls have shown a PSP-related pattern that distinguishes PSP from other atypical
parkinsonian syndromes45 and includes many of the structures identified here with ICN
fMRI.46 Overall, these investigations converge on a core set of PSP-affected structures
while suggesting that the anatomical pattern relates closely to the associated clinical
syndrome. The present study advances this framework by delineating a specific dMT-
associated large-scale network and demonstrating that task-free fMRI detects PSP-S-related
connectivity breakdowns. Our results further outline a comprehensive architecture of node
pair-wise connections for this system and show that PSP-S-related connectivity breakdowns
emphasize cortico-subcortical and cortico-brainstem interactions and correlate with clinical
severity. Although intrinsic brainstem circuits may also lose functional connectivity in PSP-
S, connectivity between brainstem node pairs was less conspicuously affected in the present
analyses. Whether this observation reflects PSP biology or methodological limitations
requires further study.
Relationship of present findings to ICN literature on Idiopathic Parkinson’s Disease (IPD)
Our PSP-S findings also fit into a context provided by a growing task-free fMRI literature
on IPD. While some studies of patients with IPD off of dopaminergic agents have shown
decreased connectivity between various cortical motor regions and basal ganglia,47, 48 others
have shown increased connectivity in sensorimotor circuits, specifically between dorsal
caudal putamen, inferior temporal gyrus, anterior cingulate cortex, and superior frontal
gyrus. These areas of increased connectivity diminished when the patients were rescanned
on dopaminergic agents.49 Fascinating recent work50 suggested increased functional
connectivity between the subthalamic nucleus and cortical motor areas in the off-medication
state in IPD, supporting the notion of basal ganglia-thalamo-cortical circuit
hypersynchronicity in IPD51 and providing a possible mechanism for STN-targeted deep-
brain stimulation. In contrast to the IPD findings, the matrix analysis performed here
suggested decreased connectivity between thalamus, basal ganglia, and pre-SMA in PSP-S,
even though half of the patients were not taking dopaminergic agents at the time of
scanning. This contrast to IPD could reflect the severe STN tau pathology in PSP and
explain, at least in part, why most patients with PSP-S do not respond to levodopa or STN
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DBS treatment52 and why we found no significant difference in mean dMT-associated
network connectivity between patients on and off dopaminergic agents.
Insights revealed by matrix and graph theoretical analyses
Networks represent multiple nodal interactions between spatially distributed and
functionally diverse regions. Seed-based ICN analysis can identify regions with abnormal
connectivity to a chosen network node such as, in this case, the dMT. While this method
works well for network identification, it provides no information about how network nodes
interact with regions other than the seed. Including matrix and graph theoretical analyses
enabled us to delineate the healthy dMT-associated network configuration and identify its
hub-like nodes in the mesothalamic junction, basal ganglia, and thalamus. These nodes may
serve as PSP-vulnerable network “epicenters” whose connectivity patterns predict
degeneration severity throughout the network, as shown for other neurodegenerative disease
syndromes.53 Graph theoretical analyses revealed PSP-S-related reductions in nodal network
traffic (total flow) and local interconnectivity (clustering coefficient). Additional work is
needed to determine whether characterizing the heathy brain functional connectome can
predict the pace and topography of progression in single patients with PSP-S and other
neurodegenerative syndromes.
Clinical correlation
In PSP-S, a dMT-associated ICN summary score correlated with the CDR sum of boxes
score, a measure of overall clinical severity. Similar but weaker correlations with the
UPDRS, PSPRS, and downward saccade velocity may have escaped significance due to the
smaller samples for which these data were available or because these measures sample too
narrow a range of PSP-S-related deficits to correlate with average network connectivity. The
outlier uncovered in these analyses had the fastest downward saccades within the PSP-S
group, consistent with this patient’s high dMT-ICN score. These observations raise
important questions, including whether this patient has a non-PSP neuropathology,
represents an atypical midbrain-sparing PSP presentation, or reflects method-related
statistical noise. Despite these lingering questions, our cross-sectional findings suggest that
ICN mapping merits further investigation as a potential disease-monitoring biomarker for
longitudinal studies and treatment trials.
Sensitivity of intrinsic connectivity analysis to early-stage network degeneration
ICN analysis outperformed VBM in discriminating PSP-S from controls in network regions
that lacked significant group-level atrophy. This finding hints at a potential role for ICN
analysis in detecting early PSP-S-related changes. Longitudinal studies are needed to
determine whether ICN data provide the “leading edge”, sensitive to early network
dysfunction and predicting where atrophy will emerge next. This capability would provide a
much-needed index of early stage disease for patients genetically at-risk for PSP or other
neurodegenerative diseases, especially once potential disease-modifying therapies enter
clinical trials.
Limitations and Future Directions
This study focused on identifying a PSP-related ICN using novel network mapping methods.
The analysis was not designed to provide a comprehensive multimodal neuroimaging
comparison or to use imaging to predict pathology. Although the typical PSP syndrome we
studied strongly predicts PSP pathology,25 some patients in this study could have had a non-
PSP histopathology, and future studies are needed to determine whether ICN measurements
can single out patients with PSP-S who lack PSP pathology. Many patients studied here took
medications to address ongoing motor or psychiatric/behavioral symptoms. These
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medications could have influenced the ICN results, yet studying only medication-free
patients with PSP-S would have proven unfeasible, even at our referral center where
recruiting patients with PSP-S represents a major research priority. The noninvasive and
repeatable nature of ICN methods make them attractive potential longitudinal biomarkers,
and future work should explore this potential by studying patients with PSP and other
network-based neurodegenerative disorders over time.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The dMT-associated ICN
The dMT was used as a seed ROI for voxel-wise task-free fMRI analyses in healthy young
(HC1, upper row) and older (HC2, middle row) controls. Results are displayed at height
threshold p < 0.0001, extent threshold p < 0.001 family-wise error-corrected at the cluster
level (yellow) and at height threshold p < 0.05, family-wise error-corrected at the voxel level
(red) to avoid omitting small but significant brainstem clusters. Corrections were performed
across the whole brain. The overlap between the voxel level results for the two control
groups (bottom row) is shown to highlight the consistency of the pattern within subcortical,
diencephalic, and brainstem/cerebellar structures central to the known PSP pathological
injury pattern. The right-most panel in the bottom row shows an axial view of the dMT seed
(yellow) used for the seed-based ICN analysis. Slice labels reflect MNI coordinates. The
right side of the images corresponds to the right side of the brain. CN, caudate nucleus;
dMT, dorsal midbrain tegmentum; DentN, dentate nucleus; GPe, globus pallidus externa;
latCRB, lateral cerebellum; Put, putamen; SC, superior colliculus; SN, substantia nigra;
STN, subthalamic nucleus; IIIN, third nerve nuclear complex.
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Figure 2. Network connectivity reductions in PSP
Examining the same dMT-associated ICN shown in Figure 1, we found connectivity
reductions in PSP distributed throughout the network. Results are displayed at p < 0.01 (dark
blue) and p < 0.05 (light blue), joint height and extent corrected at the cluster level across
the network. Slice labels reflect MNI coordinates. The right side of the images corresponds
to the right side of the brain. dAI, dorsal anterior insula; dCN, dorsal caudate nucleus; FEF,
frontal eye fields; FI, frontoinsula; IFGoper, inferior frontal gyrus (pars opercularis); IPL,
inferior parietal lobule; latOFC, lateral orbitofrontal cortex; Thal, thalamus; pACC,
pregenual ACC; preSMA, pre-supplementary motor area; SFS, superior frontal sulcus. Other
abbreviations as in Figure 1.
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Figure 3. The broader PSP-related network in health and disease
Regions showing intrinsic connectivity to the dMT in the HC2 group were isolated (A,
Supplementary Figure 1, Supplementary Table 2) and used to generate matrices representing
the connectivity strength between each ROI pair for HC2 (B), HC3 (C), and PSP (D). Color
bars in B–D indicate the Pearson correlation coefficients (r) derived for each node pair
transformed to z-scores. In (E), the node pair matrix highlights those pairs showing
significant connectivity reduction in PSP vs. HC3, corrected at the matrix level for false
discovery rate to produce a p < 0.05 (z ≥ 2.21). The color bar indicates the z-scores derived
from the two-sample t-test (PSP < HC3). Colored node pairs indicate significant reductions.
aINS, anterior insula; BG, basal ganglia; cPONS, caudal pons; MFG, middle frontal gyrus;
MTJ, mesothalamic junction; pMCC, posterior midcingulate cortex; PreCu, precuneus;
rPONS, rostral pons; RSC, retrosplenial cortex; SMG, supramarginal gyrus. Other
abbreviations as in Figures 1 & 2.
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Figure 4. The matrix-derived dMT-associated ICN architecture and connectivity reductions in
PSP
An edge-weighted force-directed algorithm was used to display the relationships among
network nodes in the healthy brain (HC2 data). Heuristically, nodes clustered together
represent more closely related subnetworks and nodes placed centrally within the overall
graph have stronger, more numerous edges characteristic of central hubs. Node diameter
represents node total flow, whereas edge thickness represents the correlation coefficient of
the node pair connected by that edge transformed to z-scores. To overlay PSP-related
deficits on the healthy brain graph, nodes were colored by the t-score resulting from the two-
sample t-test for node total flow (PSP < HC3) and thresholded at a p < 0.05, corrected for
false discovery rate across the network. Abbreviations as in Figures 1–3.
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Figure 5. Clinical Correlations to dMT-associated ICN Score
Scatterplots represent the relationships between mean network connectivity and CDR sum of
boxes score, PSPRS, and downward saccade velocity. The dMT-associated ICN score was
calculated as each subject’s mean beta value across all voxels within their dMT-associated
ICN map, masked by the ICN as defined in HC2 subjects (see Methods). Circles represent
PSP subjects; the one filled circle indicates an outlier excluded from the CDR and PSPRS
correlation analyses but included in the downward saccade velocity correlation analysis, in
which she was not an outlier. For comparison, the empty triangle represents the mean dMT-
associated ICN score for matched control subjects (HC3).
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Figure 6. Effect size comparison of dMT associated ICN reductions versus grey matter atrophy
in patients with PSP-S compared to matched controls
Upper row: We compared voxel-wise PSP-S < HC3 effect sizes produced by the dMT-
associated ICN and VBM grey matter analyses. Voxels where the dMT ICN reduction
produced a greater effect size are shown in yellow, whereas voxels where VBM afforded a
greater effect size are shown in blue. Effect size maps were thresholded to include only
those voxels that had a moderate effect size (0.5) or greater. Middle row: For comparison,
we display the corresponding views of the dMT ICN map from the HC2 network discovery
group (as shown in Figure 2; height threshold p < 0.0001, extent threshold p < 0.001,
family-wise error-corrected at the cluster level). Bottom row: The corresponding VBM grey
matter atrophy pattern in PSP-S compared to HC3 (p < 0.05, family-wise error corrected at
the voxel level across the whole brain) illustrates the relative structural integrity of regions
where ICN methods produced greater effect sizes than VBM. Slice labels reflect MNI
coordinates. The right side of the images corresponds to the right side of the brain. Note that
the effect size and VBM analyses were conducted on grey matter maps, which exclude most
brainstem regions.
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Table 1
Table Demographics and neuropsychological features for PSP and matched healthy controls (HC3).
Healthy controls (HC3) (n=36) PSP (n=18) P value, df
Age, years 68.8 (5.7) 67.3 (6.0) 0.394, 52
M:F, n 12:24 6:12 NA
Education, years 16.4 (1.7) 15.8 (2.6) 0.312, 54
Illness duration, years NA 4.8 (2.3) NA
PSP-RS NA 45.0 (13.8) NA
UPDRS NA 37.5 (15.1) NA
Downward saccade velocity, deg/s 340.3 (85.5) 90.0 (65.3) <0.001, 35
CDR, total 0 (0) 0.94 (0.6) NA
CDR, sum of boxes 0.01 (0.08) 5.9 (3.7) NA
MMSE (max = 30) 29.5 (0.8) 26.1 (4.5) <0.001, 54
CVLT-SF, four learning trials, total (max = 36) NC 18.5 (11.7) NA
CVLT-SF, 10 minute recall, score (max = 9) NC 4.2 (3.0) NA
Modified Rey-O copy (max = 17) 15.3 (0.9) 11.4 (4.2) <0.001, 34
Modified Rey-O 10 minute recall (max = 17) 12.6 (2.6) 8.4 (3.7) 0.001, 27
Digit span backward 5.5 (1.4) 3.6 (0.9) <0.001, 39.4
Modified trails (correct lines per minute) 36.9 (11.6) 13.8 (6.4) <0.001, 47
Design fluency (max = 30) 10.9 (3.7) 5.8 (2.3) <0.001, 45
Letter fluency (‘D’ words in 1 minute) 15.5 (5.0) 6.6 (4.8) <0.001, 40
Semantic fluency (animals in 1 minute) 23.6 (5.3) 10.0 (4.8) <0.001, 48
Abbreviated BNT (max = 15) 14.7 (0.6) 13.6 (2.2) 0.015, 50
Calculations (max = 5) 4.9 (0.3) 3.9 (0.8) <0.001, 47
Translational motion (mRMS), mm 0.328 (0.188) 0.328 (0.276) 0.52, 54
Rotational motion (mEuler), degrees 0.13 (0.09) 0.16 (0.15) 0.96, 54
Values represent mean (s.d.). Non-parametric tests used where appropriate.
Abbreviations: BNT, Boston Naming Test; CDR, Clinical Dementia Rating; CVLT-SF, California Verbal Learning Test-Short form; deg/s, degrees
per second; mEuler, mean Euler angle; MMSE, Mini-Mental State Examination; mRMS, mean root mean square; NA, not applicable; NC, not
collected; PSP-RS, PSP Rating Scale; UPDRS, Unified Parkinson’s Disease Rating Scale.
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